Document is current
Any future updates will be listed below
-
Authors
Dang, Ha Thuy
Phung, Thuy Thi Bich
Tran, Dien Minh
Bui, Anh Thi Phuong
Vu, Yen Hai
Luong, Minh Thi
Nguyen, Hang Minh
Trinh, Huong Thi
Vo, Hao Thi Ngoc
Nguyen, Trang Thi Thu
Nguyen, Anh Hoa
Tung, Pham Dinh
Tran, Linh Huyen
Van Nguyen, Anh Thi
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05812820 at ClinicalTrials.govDocuments that mention this clinical trial
High-dose multi-strain Bacillus probiotics enhance treatment and reduce antibiotic usage in children with persistent diarrhea through immune and microbiota modulation
https://doi.org/10.1038/s41598-025-15199-y
Promising clinical and immunological efficacy of Bacillus clausii spore probiotics for supportive treatment of persistent diarrhea in children
https://doi.org/10.1038/s41598-024-56627-9
-
Funding
Funding for this research was provided by:
ANABIO R&D Ltd. Company, Viet Nam (ANABIO/RG-2022-06)
- License Information
-
More Information
Article History
Received: 30 January 2025
Accepted: 6 August 2025
First Online: 18 August 2025
Declarations
:
: LiveSpo DIA30 is produced by LiveSpo Pharma Ltd., in which A.H.N. is a founder and scientific director. A.T.V.N. serves as a scientific consultant for LiveSpo Pharma Ltd., while A.T.V.N., A.T.P.B and H.T.N.V. are affiliated with the funder, ANABIO R&D Ltd. All the remaining authors declare no conflict of interest. LiveSpo Pharma Ltd. had no role in study design, data collection, data analysis, data interpretation, or writing of the report.
